Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
Business Wire•23/09/2026•16:30 ET
1
Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
Innovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and development
Get started
Create a free account to read the full story and Whiz Insights.